To reduce time, cost, and patient deaths during drug development through System of Systems approach and high prediction accuracy
To use quantitative forecasting, AI, and innovative laboratory tools to heal the world of life-threatening diseases at an affordable price
We believe in the essence of ubuntu/unhu, recognizing and respecting the inherent humanity of every individual. Through fostering interconnections, we serve human health with empathy and trust.
Our commitment to continuous, groundbreaking innovation keep driving us to develop precise quantitative and physical tools and platforms. These advancements push the frontiers of drug development science, enhancing patient outcomes.
Embracing a System of Systems approach, we integrate data, non-animal wet lab tools, virtual lab twins, mathematics, and artificial intelligence to achieve superior predictions in drug development outcomes, and shorten time from discovery to the bedside three fold. This dedication benefits biopharma companies and the global population of patients.
We prioritize preserving human life and well-being by reducing the need for human volunteers at risk of injury or harm during clinical trials. Our approach embodies the role of Healers in safeguarding lives during and after drug development.
Accessibility and Affordability
Striving for a better future, we are committed to significantly lowering the cost of drug development by up to 90% and reducing drug prices. Our goal is to make essential treatments more affordable and accessible, positively impacting mankind.
Johnson was previously CFO of a data center solutions and IT services provider, which he co-founded and grew internationally to over $200 million in revenues with operations in North America and Brazil and exited. Johnson began his career at blue-chip companies, first as an engineer at General Electric and later as an investment banker at JP Morgan Chase and Merrill Lynch. He began his entrepreneurial career as an independent sponsor where he acquired, invested in, operated, and sold numerous companies in energy services and technology sectors with an aggregate enterprise value of $600 million. Johnson is holder of a US patent for an innovative lighting technology as an engineer at General Electric. VIEW HERE
Physician and bench scientist.
Extensive training and experience in work with both DNA and RNA viruses and parasitesHas published dozens of seminal papers on epidemiology, molecular pathogenesis, diagnosis and treatment of important human viruses including human polyomavirus JC (JCV), West-Nile virus (WNV) and dengue virus.Explored role of serotonin receptor blocker risperidone against JCV and roles of minocycline and tumor necrosis factor a receptor 2 in WNV and is expert in virus culture, characterization and quantificationExpert in laboratory hollow fiber models of tuberculosis, Mycobacterium avium-complex, Mycobacterium abscessus, and Mycobacterium kansasii
He holds several patents for diagnostics, and for monoclonal antibodies that bind to FCER1. Dr. Gumbo is also a published poet and novelist. He also writes the introduction chapter to anti-infective therapy chapter, and the treatment of mycobacterial infections chapter in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, referred to as the “Bible of pharmacology." He has authored greater than 200 scientific publications on PubMed: VIEW HERE
Gesham Magombedze, PhD, joins Praedicare with over 15 years of experience in Mathematical Modeling and Simulation in Systems Biology, Immunology and Infectious Diseases, and over 8 years in Pharmaceutical, Biotechnology and Mechanistic disease translational modeling to inform drug development. His expertise is in developing and validating mechanistic mathematical models that replicate human disease, therefore creating and simulating virtual patients on the computer. This creates a strong mathematical modeling framework to (i) predict drug mechanism of actions, (ii) predict the disease underpinning mechanisms, (iii) carry out virtual biological experiments, (iv) predict human doses, (v) precise translation of preclinical to clinical results and (vi) simulation clinical trials through simulating virtual human populations. This helps to inform drug development through research and discovery to clinical trials.
He developed novel translational approaches using non-linear transformation factors for translation of preclinical experimental model results to human clinical outcomes. As well as methods combining mechanistic dynamic models with machine learning algorithms to predict and characterize biomarkers for long term treatment outcomes and biomarkers for real time decision making during clinical trials. Before joining the leadership at Praedicare, he worked at Gilead Sciences as the lead mathematical modeling Senior Scientist/Associate Director across Virology, Inflammation and Oncology therapeutic areas, for drug development and translation. Prior to that at the Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Institute of Immunology Research, he supported the discovery of novel TB drug combination regimens and the repurposing of different anti mycobacterial drugs to treat non-tuberculosis mycobacteria. Gesham holds an Adjunct Assistant Professor position at Texas Tech University, Health Sciences, School of Pharmacy and trained as a postdoctoral fellow at Imperial College London, MRC Center for Outbreak analysis and Modeling, Department of Infectious Diseases and Modeling in UK, at the National Institute for Mathematical and Biological Synthesis, University of Tennessee, Knoxville, USA and at the University of Cape Town, Institute of Infectious Diseases and Molecular Medicine and Computational Biology, South Africa. Gesham holds a PhD in Mathematical Biology from the National University of Science and Technology, Bulawayo, Zimbabwe and has more than 50 scientific publications.
Wesley, an entrepreneur, and IT enthusiast was previously a financial advisor and before that a medical doctor. He has consulted and financed multiple early stage and growth companies. He is founder of ProHelium, a company focused on financing, drilling and producing helium on properties throughout the United States, including 14 wells in Arizona and Colorado. Wesley began his career after medicine as Chief Information Officer for a regional brokerage firm maintaining a network of over 200 computers at 6 locations. He progressed to being a licensed financial advisor and money manager, rising through the ranks to become a Vice President and Financial Advisor at Southwest Securities and Ameriprise Financial over two decades. After medical school, he joined the clinical staff at UT Southwestern in the Department of Epidemiology where he led the design, development, and maintenance of a database on war veteran’s Gulf War Syndrome. The data led to over 60 scientific publications, including the Journal of the American Medical Association (JAMA), where Wesley published the first paper based on this data, becoming the youngest physician at the medical school to publish in JAMA. Wesley holds a Doctor of Medicine degree from the University of Texas Southwestern Medical School and a BS in Computer Science from Texas A&M University.
Number of Biopharma
Companies Worked With
Number of Projects
Number of Biopharma
Companies Worked With
Number of Projects